Alex Warren strapped in. Terrell Carter changed a tire. Matty Rossi hit the sauna. Kenneth Sky opened the door. Brandon ...

"There is no doubt Trai Hume can make that step up to European football," believes BBC Sport Northern Ireland journalist Andy Gray. The full-back, who has played a crucial role in Sunderland's journey ...

ATTR-cardiac amyloidosis (ATTR-CM) is a progressive heart condition often mistaken for normal aging. For years, communication in the category has focused on urgency and decline, leaving patients with ...

BridgeBio Pharma currently markets the ATTR-CM treatment Attruby, which has been on a strong sales trajectory since its 2024 approval. (iStock/Getty Images Plus) BridgeBio Pharma is teaming up with ...

Diagnosing ATTR-CM early allows clinicians to initiate treatment before substantial amyloid deposits accumulate in the myocardium. The lack of specificity in the clinical presentation of transthyretin ...

Kevin M. Alexander, MD, reflects on ACC data for ATTR-CM and its implications for patient care, stressing that clinical trials and extension analyses show ATTR therapies extend survival, improve ...

In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...

The model had an area under the receiver operating characteristic curve of 0.83 in a high-risk subgroup of patients with conditions that mimic ATTR-CM. An artificial intelligence model trained to ...

Kevin M. Alexander, MD, reports on new data for ATTR cardiac amyloidosis from the recent ACC conference. The ATTRibute-CM study showed that acoramidis provides continued, significant benefits at 54 ...

An artificial intelligence model trained to analyze ECG images identified which patients had ATTR-CM. The model had an area under the receiver operating characteristic curve of 0.83 in a high-risk ...

Based on market patterns in other diseases such as pulmonary arterial hypertension and atrial fibrillation, Alnylam believes that the entire ATTR-CM category is still in its infancy. (iStock / Getty ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...